The development of GRPR-targeting radiopharmaceuticals has been focused on the use of antagonist sequences as the targeting vector in the past decade, partly due to their higher in vivo stability [29], potentially higher tumor uptake due to more binding sites than those available for agonists [30], and/or less short term adverse effects [31,32]. The gene discussed is GRPR; the disease is neoplasm.